At MediMix, we are dedicated to keeping Belgian healthcare professionals at the forefront of medicine. Our team brings you high-value insights from leading congresses worldwide, across key disease areas including oncology. In collaboration with Belgian and international experts, we transform the latest data into practical knowledge.
Latest publications
The randomised, double-blind, phase III KEYNOTE-937 trial evaluated pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who achieved a complete radiological response after surgical resection or
The BREAKWATER study evaluated first-line treatment strategies in BRAF V600E-mutant metastatic colorectal cancer.
The Chinese, randomised, phase II NEOSUMMIT-01 trial evaluated perioperative chemotherapy with or without the PD-1 antibody toripalimab in patients with locally advanced, resectable gastric or gastro-oesophageal junction (GEJ) adenocarcinoma.
General Session 3 of the 2025 San Antonio Breast Cancer Symposium presented important data spanning cancer prevention, screening, fertility preservation, and new systemic therapies for hormone receptor–positive breast cancer.
General Session 2 of the San Antonio Breast Cancer Symposium focused on surgical de-escalation and innovative radiation strategies in breast cancer.